目的 分析2012—2016年天津市胸科醫(yī)院調(diào)血脂藥物的使用情況及用藥趨勢，促進其合理應(yīng)用。方法 對2012—2016年天津市胸科醫(yī)院調(diào)血脂藥物的銷售金額、用藥頻度（DDDs）、限定日費用（DDC）等進行統(tǒng)計分析。結(jié)果 2012—2016年，調(diào)血脂藥物的銷售金額、占西藥銷售金額的比例總體上呈上升趨勢，但銷售占比在2016年有所下降；各類調(diào)脂藥物的銷售情況分析顯示，除煙酸類調(diào)血脂藥物外，其余均呈上升趨勢；阿托伐他汀的DDDs最高，瑞舒伐他汀的DDDs增幅最大；他汀類等一線的調(diào)血脂藥物的銷售金額及比例始終居于首位，同時其DDC呈下降趨勢。結(jié)論 2012—2016年天津市胸科醫(yī)院調(diào)血脂藥物的使用基本合理，經(jīng)過價格的調(diào)整，患者的經(jīng)濟負擔減輕。

Objective To analyze the situation and developing trend of regulating blood-lipid drugs in Tianjin Thoracic Hospital from 2012 to 2016, and to promote the reasonable application. Methods Consumption sum, frequency of drug use (DDDs), and defined daily cost (DDC) of regulating blood-lipid drugs in Tianjin Thoracic Hospital from 2012 to 2016 were analyzed.Results From 2012 to 2016, consumption sum and the ratio of regulating blood-lipid drugs in Western medicine sales were overall on the rise, but the sales proportion declined in 2016. Sales of all kinds of regulating blood-lipid drugs revealed that besides nicotinic acid regulating blood-lipid drugs, the rest had the rising trend. DDDs of atorvastatin was the highest, and DDDs amplification of rosuvastatin was the largest. Consumption sum and proportion of statin regulating blood-lipid drugs were always in the first place, and at the same time DDC was on the decline. Conclusion The utilization of regulating blood-lipid drugs in Tianjin Thoracic Hospital from 2012 to 2016 is rational on the whole. Through adjusting the prices, the financial burden of patients is reduced.